| ¿µ¹® | thyroid gland | ÇÑ±Û | °©»ó»ù |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ¸ö¿¡¼ °¡Àå Å« ³»ºÐºñ»ùÀ¸·Î ¸ñÀÇ ¾ÕÂÊ, ¾Æ·¡ÂÊ¿¡ À§Ä¡Çϰí ÀÖÀ¸¸ç 2¿±À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. °¢ ¿±Àº ±â°üÀÇ ¾çÂÊ¿¡ ÀÖÀ¸¸ç Á¼Àº Àß·è¿¡ ÀÇÇØ ¾Õ¿¡¼ ¿¬°áµÇ¾î ÀÖ´Ù. °©»ó»ùÈ£¸£¸óÀΠƼ·Ï½Å(thyroxine)À» ºÐºñÇϰí ÀúÀåÇϸç, Çʿ信 µû¶ó ¹æÃâÇÑ´Ù. ¶ÇÇÑ °©»ó»ùÀº Ƽ·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)µµ ºÐºñÇÑ´Ù. º´ÀûÀÎ »óÅ¿¡¼ Å©±â°¡ ´ë°³ Áõ°¡Çϰí, ÀϺο¡¼´Â µµ¸®¾î À§ÃàµÇ¸ç, ÅëÁõÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. |
||
| ¿µ¹® | thyroid carcinoma | ÇÑ±Û | °©»ó»ù¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | °©»ó»ù¿¡ »ý±ä »óÇǼ¼Æ÷·Î ÀÌ·ç¾îÁø ¾Ç¼ºÁ¾¾ç¹°. º´¸®Á¶Á÷ÇÐÀûÀÎ ÇüÅ¿¡ µû¶ó À¯µÎ»ó, ¼ÒÆ÷»ó, ¿ªÇü¾ÏÁ¾ ¹× ¼öÁú¾ÏÁ¾, ¸²ÇÁÁ¾ µîÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ´Ù¾çÇÑ ¿øÀÎÀÌ ÀÖÀ¸³ª, ÀϺο¡¼´Â ¹æ»ç¼±Æø·Î¿¡ ÀÇÇØ ¹ß»ýÇÑ´Ù. Ä¡·á´Â ¼ö¼ú, ¹æ»ç¼º ¿Á¼Ò, T4 ¾ïÁ¦¿ä¹ý µîÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | thyroid hormone | ÇÑ±Û | °©»ó»ùÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ±¤ÀÇÀÇ °©»ó¼±È£¸£¸óÀº Ƽ·Ï½Å(thyroxine(T4)), »ï¿äµåƼ·Î´Ñ(triiodothyronine (T3)), Ƽ·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)ÀÇ 3°¡ÁöÁß Çϳª¸¦ ¸»Çϳª ´ë°³ÀÇ °æ¿ì ÇùÀÇÀÇ ¶æÀ¸·Î »ç¿ëµÇ¸ç ÀÌ °æ¿ì Ƽ·Ï½Å°ú »ï¿äµåƼ·Î´ÑÀ» ÁöĪÇÑ´Ù. °©»ó¼± È£¸£¸óÀº °ÅÀÇ ¸ðµç ¸ö¼¼Æ÷¿¡¼ÀÇ ¹ÙÅÁÁú´ë»ç¿¡ °ü¿©ÇÏ¿© ¿¡³ÊÁö»ý¼ºÀ» Áõ°¡½ÃŰ°í ¼ºÀå ¹ßÀ°À» ÃËÁøÇÑ´Ù. À̰ÍÀº ³úÇϼöü¿¡¼ ºÐºñµÇ´Â °©»ó»ù ÀÚ±ØÈ£¸£¸ó¿¡ ÀÇÇØ ÇÕ¼º ¹× ºÐºñ°¡ ÃËÁøµÈ´Ù. ¼·ÃëÇÏ¿© ü³»¿¡ µé¾î¿Â ¿ä¿Àµå°¡ ´Éµ¿¿î¹Ý¿¡ ÀÇÇØ °©»ó»ù¼¼Æ÷³»·Î µé¾î°¡ ¼¼Æ÷³»¿¡ ÀÖ´Â ´Ü¹éÁúÀÎ °©»ó»ù ±Û·Îºí¸°°ú °áÇÕÇÏ¿© °©»ó»ùÈ£¸£¸óÀ¸·Î ÇÕ¼ºµÈ´Ù. ¿ä¿Àµå°¡ 3ºÐÀÚ °áÇÕÇÑ °ÍÀ» T3, 4ºÐÀÚ °áÇÕÇÑ °ÍÀ» T4¶ó ºÎ¸§. ºÐºñµÇ´Â °©»ó¼± È£¸£¸óÁß 90%ÀÌ»óÀÌ T4ÀÌ´Ù. Ç÷ÁßÀ¸·Î ºÐºñµÈ °©»ó»ùÈ£¸£¸óÀº Ç÷Áß ´Ü¹éÁú°ú °áÇÕÇϴµ¥ ´ëºÎºÐÀº Ƽ·Ð½Å°áÇÕ±Û·Îºí¸°°ú °áÇÕÇϸç ÀϺδ ¾ËºÎ¹Î°ú °áÇÕÇÑ´Ù. Àü¹ÝÀûÀÎ ´ë»çÀ²À» ÃËÁø½ÃŰ¸ç ¾î¸°ÀÌ¿¡¼´Â ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ƯÈ÷ ¾î¸°ÀÌ¿¡¼ ¸ô´Ü¹éÁú ÇÕ¼ºÀ» ÃËÁøÇÏ¸ç ³úÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ±â´ÉÀ» ÇÔÀ¸·Î½á, ¼±Ãµ¼º °©»ó»ùÀúÇÏÁõ(cretinism)À» Á¶±â ¹ß°ßÇÏ¿© Ä¡·áÇÏÁö ¸øÇϸé Á¤½ÅÁöü°¡ À¯¹ßµÈ´Ù. °©»ó»ù°ú´ÙÁõÀÇ Áõ»óÀº ü³» ´ë»ç°¡ Ç×ÁøµÇ¾î ½Ä¿åÀÌ Áõ°¡Çϳª üÁßÀÌ °¨¼ÒÇÏ°í ½ÉÀå¹Úµ¿¼ö°¡ Áõ°¡ÇÏ°í ´õÀ§¸¦ ÂüÁö ¸øÇϸç, °©»ó»ù±â´ÉÀúÇÏÁõÀÇ Áõ»óÀº À§¿Í ¹Ý´ë·Î ½Ä¿åÀÌ °¨¼ÒÇϰí üÁßÀÌ Áõ°¡ÇÏ¸ç ½ÉÀå¹Úµ¿¼ö°¡ °¨¼ÒÇϰí ÃßÀ§¸¦ ÂüÁö ¸øÇϸç ÇǺο¡ ´Ü¹éÁúÀÌ ÃàÀûµÇ¾î Á¡¾×ºÎÁ¾ÀÌ À¯¹ßµÈ´Ù. |
||
| CG | cardiography; cardiogreen; choking gas; choriogenic gynecomastia; chorionic gonadotropin; chromogran... |
|---|---|
| CI | cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar... |
| coll | collateral; collection, collective; college; colloidal |
| 131I | radioactive Iodine(used in Thyroid uptake, Liver & Kidney Scans & Treatment of malignant & nonmalig... |
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
| ABCD | Amphotericin B Colloidal Dispersion |
|---|---|
| CCG | Cationic colloidal gold |
| CBS | Colloidal bismuth subcitrate |
| CG | colloidal gold |
| C.I. | colloidal iron |
| chromic phosphate P 32 colloidal suspension | A pure beta-emitting colloidal, nonabsorbable radiopharmaceutical administered into body cavities such as the pleural or peritoneal spaces to control malignant effusions. See: sodium phosphate P 32. (05 Mar 2000) |
|---|---|
| colloidal | <chemistry> Of the nature of a colloid. (18 Nov 1997) |
| colloidal dispersion | <chemistry> A mixture containing particles larger than those found in a solution but small enough to remain suspended for a very long time. (09 Oct 1997) |
| colloidal gel | A colloid that has developed resistance to flow because of chemical or thermal change. (05 Mar 2000) |
| colloidal gold reaction | A test (now obsolete) based on precipitation of cerebrospinal fluid protein when mixed with colloidal gold. Abnormalities in this reaction were observed in patients with syphilis, multiple sclerosis, poliomyelitis, and encephalitis. (05 Mar 2000) |
| colloidal metal | A colloidal solution of a metal obtained by passing electric sparks between terminals of the metal in distilled water. Synonym: electrosol. (05 Mar 2000) |
| colloidal radioactive gold | A radioactive isotope of gold emitting negative beta particles and gamma radiation, with a half-life of 2.7 days; formerly used for irradiation of closed serous cavities in the palliative treatment of ascites and pleural effusion due to metastatic malignancies, and for liver scans. Synonym: 198Au colloid, colloidal radioactive gold. (05 Mar 2000) |
| colloidal silicon dioxide | A submicroscopic fumed silica prepared by the vapor-phase hydrolysis of a silicon compound; used as a tablet diluent and as a suspending and thickening agent. (05 Mar 2000) |
| colloidal silver iodide | An antiseptic used for treatment of inflammation of the mucous membranes. (05 Mar 2000) |
| colloidal solution | A dispersoid, emulsoid, or suspensoid. Synonym: colloidal dispersion. (05 Mar 2000) |
| Mowry's colloidal iron stain | <technique> A stain used for demonstrating acid mucopolysaccharides. (05 Mar 2000) |
| Hale's colloidal iron stain | <technique> A stain used to distinguish acid mucopolysaccharides such as hyaluronic acid; may be combined with PAS to also visualise carbohydrate-containing proteins and glycoproteins. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| antibodies | Any of numerous protein molecules produced by the B-cells as a primary immune defense. (16 Dec 1997) |
| antibodies, anticardiolipin | Antiphospholipid antibodies found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase immunoassay employing the purified phospholipid antigen cardiolipin. (12 Dec 1998) |
| thyroid colloidal antibodies |
antibodies to antigens in the thyroid colloid such as thyroglobulin or CA2, seen in Hashimoto's disease.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|